Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Shares Outstanding for 4 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 230.17% to $5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.4 million, a 230.17% increase, with the full-year FY2025 number at $2.0 million, changed N/A from a year prior.
  • Shares Outstanding was $5.4 million for Q4 2025 at Neuphoria Therapeutics, up from $2.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $969.4 million in Q2 2022 to a low of $454465.1 in Q2 2023.
  • A 4-year average of $123.1 million and a median of $1.9 million in 2025 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: plummeted 99.95% in 2023, then soared 230.17% in 2025.
  • Neuphoria Therapeutics' Shares Outstanding stood at $969.4 million in 2022, then crashed by 99.95% to $454465.1 in 2023, then skyrocketed by 258.37% to $1.6 million in 2024, then skyrocketed by 230.17% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Shares Outstanding are $5.4 million (Q4 2025), $2.4 million (Q3 2025), and $2.0 million (Q2 2025).